We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

donderdag 14 september 2017

The Lancet: [Comment] Global deworming: moving past albendazole and mebendazole

[Comment] Global deworming: moving past albendazole and mebendazole
Since the 2001 adoption of the World Health Assembly (WHA) resolution calling for the global deworming of children affected by soil-transmitted helminth (STH) infections and schistosomiasis,1 the world's public health leaders have gradually responded. Although we are still behind schedule in terms of the WHA's original 2010 targets, WHO continues to report progress—in 2015, approximately 59% of the world's children requiring treatment received access to deworming medicines for their STH infections,2 mostly single-dose albendazole or mebendazole (each an anthelmintic drug in the benzimidazole drug class).
Read more

[Articles] A fatal outbreak of ST11 carbapenem-resistant hypervirulent in a Chinese hospital: a molecular epidemiological study
The ST11 carbapenem-resistant hypervirulent K pneumoniae strains pose a substantial threat to human health because they are simultaneously hypervirulent, multidrug resistant, and highly transmissible. Control measures should be implemented to prevent further dissemination of such organisms in the hospital setting and the community.
Read more

[Articles] AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated malaria: a randomised, phase 2, non-inferiority clinical trial
The per-protocol analysis suggested non-inferiority of AQ-13 to artemether plus lumefantrine. By contrast, the intention-to-treat analysis, which included two participants who withdrew and three who were lost to follow-up from the AQ-13 group, did not meet the criterion for non-inferiority of AQ-13, although there were no AQ-13 treatment failures. Studies with more participants (and non-immune participants) are needed to decide whether widespread use of modified 4-aminoquinolones should be recommended.
Read more

[Comment] Treating malaria: new drugs for a new era
In The Lancet Infectious Diseases, Ousmane Koita and colleagues1 reported the results of a randomised, phase 2, non-inferiority clinical trial. They compared AQ-13, a next generation 4-aminoquinoline (4-AQ) compound, with artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in 66 Malian men.
Read more

[Corrections] Corrections
Saunders MJ, Wingfield T, Tovar MA, et al. A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study. Lancet Infect Dis 2017; published online Aug 18. http://dx.doi.org/10.1016/S1473-3099(17)30447-4—The support and grants in the Acknowledgments section should have been assigned as follows: This study was supported by Wellcome Trust awards 057434/Z/99/B (MAT, KZ, RM, TRV, JSF, RHG, and CAE), Z070005/Z/02/Z (MAT, TRV, JSF, RHG, and CAE), 078340/Z/05/Z (MAT, KZ, RM, TRV, JSF, and RHG, CAE), 105788/Z/14/Z (SD, RHG, and CAE), 201251/Z/16/Z (MJS, RHG, and CAE), the Department for International Development Civil Society Challenge Fund (MAT, KZ, RM, TRV, CAE), the Joint Global Health Trials consortium (Medical Research Council, Department for International Development, and Wellcome Trust award MR/K007467/1 [TW, MAT, KZ, RM, TRV, RHG, and CAE]), the Bill & Melinda Gates Foundation (award OPP1118545 [TW, MAT, RM, TRV, and CAE]), Imperial College National Institutes of Health Research Biomedical Research Centre (JAF and CAE), the Foundation for Innovative New Diagnostics (MAT, KZ, TRV, and CAE), the Sir Halley Stewart Trust (CAE), WHO (CAE), the STOP TB partnership's TB REACH initiative funded by the Government of Canada (W5_PER_CDT1_PRISMA [MAT, RM, and CAE]), and Innovation For Health And Development (MJS, TW, and CAE).
Read more